Zepbound hair loss at month 3: where tirzepatide shedding sits on the clock

Also searched as: ZepboundMounjarotirzepatideZepbound hair loss month 3

The Zepbound label lists hair loss in 4–5% of patients versus 1% on placebo, far more often in women (7.1%) than men (0.5%), and says it was associated with weight reduction; weight-loss shedding is typically noticed 2–4 months after the loss begins.

Plot my dates on the Shed Clock

The timeline

Stage	When (typically)	What's happening
Trigger	Weight loss	The Zepbound label says hair-loss reports were associated with weight reduction. [U.S.]
Onset	Commonly 2–4 months after the loss begins	DermNet: increased hair fall is noticed 2 to 4 months after a triggering event — so month 3 sits squarely in the usual window. [DermNet]
Settling	Typically over 6–9 months	Shedding commonly tapers over 6–9 months once the trigger is no longer active. [DermNet]

Semaglutide vs tirzepatide: what the labels actually say

	Wegovy (semaglutide 2.4 mg)	Zepbound (tirzepatide)
Hair loss on drug	3.3% pooled adults [U.S.]	4–5% by dose [U.S.]
Placebo	1% [U.S.]	1% [U.S.]
Women vs men	4% vs 0.9% [U.S.]	7.1% vs 0.5% [U.S.]
Label's explanation	Associated with weight reduction	Associated with weight reduction

Neither label gives a week when shedding starts — the timing comes from how telogen effluvium works, not from the trials. Mounjaro contains the same active ingredient as Zepbound.

Month 3 in plain terms

Hairs pushed into the resting phase around the time weight loss sped up are now being released — DermNet notes the new hairs coming through push the old club hairs out, so this fall is partly a sign of regrowth [DermNet].
Losing 20 pounds or more is itself on the AAD's list of common shedding triggers, whatever caused the weight loss [American].
If you are a woman, the label numbers suggest you are much more likely than a man to notice it [U.S.].

Key facts

In the label's adverse-reaction table, hair loss was reported in 5%, 4% and 5% of patients on Zepbound 5 mg, 10 mg and 15 mg, versus 1% on placebo. [U.S.]
Across the two pooled weight-reduction studies, hair loss was reported in 7.1% of women versus 0.5% of men on Zepbound. [U.S.]

Normal vs. warning signs

Commonly normal

Diffuse shedding over the whole scalp, starting a couple of months into steady weight loss
Shed hairs with a small white bulb at the root
A wider-looking part with no bald patches
Short new hairs appearing along the hairline later on

Warning signs — get checked

Patches or smooth bald spots
Scalp pain, redness, burning or scaling
Loss of eyebrows, eyelashes or body hair
Shedding still heavy well past about 9 months
Feeling faint, very tired or unable to eat enough protein

Find a trichologist →

What may help

Talk to your prescriber before any dose change — do not stop or adjust on your own.
Ask whether iron, B12, folate or thyroid tests make sense; DermNet advises correcting any abnormality found.
Keep protein intake adequate while appetite is low, as DermNet recommends for telogen effluvium.

Looking for scalp-care products? Our sister brand Advanced Trichology makes them. Disclosure: sister brand

Related triggers

Medications

Ferritin & iron

Frequently asked questions

Is Zepbound hair loss at month 3 normal?

Month 3 falls inside the 2–4 month window DermNet gives for shedding after a trigger such as rapid weight loss. The Zepbound label reports hair loss in 4–5% of patients versus 1% on placebo.

Does Mounjaro cause hair loss like Zepbound?

Mounjaro and Zepbound both contain tirzepatide. The Zepbound weight-management label lists hair loss and links it to weight reduction.

Is tirzepatide hair loss worse than semaglutide?

On the labels, hair loss was 4–5% on Zepbound and 3.3% on Wegovy, each versus 1% on placebo. These come from different trials, so they are not a head-to-head comparison.

When does Zepbound hair loss stop?

Weight-loss shedding commonly tapers over 6–9 months once weight stabilises, per DermNet's description of telogen effluvium.

Should I stop Zepbound because of hair loss?

Never change a prescribed medication on your own. Raise it with your prescriber, who can look for other causes too.

Sources

U.S. FDA / DailyMed. ZEPBOUND (tirzepatide) prescribing information — Adverse reactions: Hair loss
U.S. FDA / DailyMed. WEGOVY (semaglutide) prescribing information — Adverse reactions: Hair loss
DermNet (Chang F-L, Oakley A, 2019). Telogen effluvium
American Academy of Dermatology. Do you have hair loss or hair shedding?